Human Psychopharmacology: Clinical and Experimental
May 9, 2001
Thomas Heffernan, Jonathan Ling, Andrew Scholey
57 citations
Abstract Chronic use of MDMA (3,4‐methylenedioxymethamphetamine), or ‘ecstasy’, is associated with significant cognitive impairments, particularly in laboratory and field tests of memory for previously encoded material. Less is known about the effects of a history of MDMA use on aspects of everyday cognitive functioning–of which prospective memory (typically characterised as ‘remembering to do...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
April 2001
E D O'Loinsigh, G Boland, J P Kelly et al.
1. The ability of N-ethyl (MDEA) and N-butyl (MDBA) analogues of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') to induce acute behavioural changes and increases in body temperature, and to cause serotonergic neurotoxicity, was assessed in young adult male Wistar rats. The in vitro ability of MDMA analogues to evoke presynaptic monoamine release from crude rat forebrain synaptosomal...
Psychopharmacology
January 2001
Tanya L. Wallace, Gary A. Gudelsky, Charles V. Vorhees
The long-term neurochemical effects produced by the repeated administration of methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) are well documented; however, the functional consequences have not been clearly defined. The present study was designed to investigate whether rats treated with a monoamine-depleting regimen of MA or MDMA exhibit disturbances in locomotor activity...
Journal of Psychoactive Drugs
2001
G Vaiva, V Boss, D Bailly et al.
Over the last 10 years, Europe has witnessed the development of the ecstasy phenomenon; this term is used to describe several products sharing more or less the same effects. The most widely used and hence the most well known is 3,4 MDMA, but MDA, MDEA, MBDB and even 2CB or nexus are available. The psychopathological consequences of MDMA use in man are relatively poorly understood. The case...
Journal of pharmacological and toxicological methods
2001
Justin R Eckler, H Greizerstein, R A Rabin et al.
Indolamine and phenethylamine hallucinogens are drugs of abuse and, as well, mimic some aspects of idiopathic psychosis. To assist in investigating the mechanisms of action of (-)2,5-dimethoxy4-methylamphetamine ([-]-DOM), a member of the phenethylamine class of serotonergic hallucinogens, a sensitive and precise method for determining its levels in the brain tissue is required. We now describe...
The Alkaloids: Chemistry and Biology
2001
Scott Helsley, R A Rabin, Jerrold C Winter
4 citations
The results of the studies described here support the hypothesis that ibogaine produces its effects via selective interactions with multiple receptors. It appears that 5-HT2A, 5-HT2C, and sigma 2 receptors are involved in mediating the stimulus effects of ibogaine. In addition, opiate receptors may also be involved. In contrast, sigma 1, PCP/MK-801, 5-HT3, and 5-HT1A receptors do not appear to...
Pediatric Emergency Care
October 1, 2000
Michael H Shannon
51 citations
Ecstasy (MDMA) is an amphetamine derivative of growing popularity. The drug produces a range of toxicities when taken either in standard doses or overdose. In overdose it has major toxicity, producing several different life-threatening manifestations. Hepatotoxicity and hyponatremia are common but poorly understood consequences of MDMA overdose. The drug can produce long-term, if not permanent,...
Psychopharmacology
September 7, 2000
M. Morgan
Abstract. Rationale: Recreational use of "ecstasy" (3,4-methylenedioxymethamphetamine; MDMA) has become increasingly widespread. Until recently, however, little was known about the possible persistent psychological effects of extensive use of this drug. Objective: The aim of the present review is to evaluate recent empirical evidence concerning the persistent psychological sequelae of...
Annals of the New York Academy of Sciences
September 1, 2000
Michael H. Baumann, John Pablo, S F Ali et al.
37 citations
Ibogaine (IBO) is a plant-derived alkaloid that is being evaluated as a possible medication for substance use disorders. When administered peripherally to monkeys and humans, IBO is rapidly converted to an o-demethylated metabolite, 12-hydroxyibogamine (NORIBO). We have found in rats that peak blood levels of NORIBO can exceed those of the parent compound, and NORIBO persists in the bloodstream...
Annals of the New York Academy of Sciences
September 1, 2000
Stanley D Glick, Isabelle M Maisonneuve, Karen K. Szumlinski
89 citations
18-MC, a novel iboga alkaloid congener, is being developed as a potential treatment for multiple forms of drug abuse. Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). Both ibogaine...